Estradiol Valerate

Estradiol valerate is an estrogen ester, formed by attaching a valeric acid group to the estradiol molecule ^[1][3]. It is classed as a prodrug because it has little activity of its own; after administration it is rapidly hydrolyzed to release natural 17β-estradiol, which is the active hormone ^[1][2]. Because part of the molecule's weight is the valerate group, a given mass of estradiol valerate delivers somewhat less estradiol than the same mass of estradiol ^[1]. It is regarded as a bioidentical estrogen because the hormone it releases is identical to the body's own estradiol ^[1].

Estradiol valerate was first described around 1940 and introduced for clinical use in the 1950s by the pharmaceutical company Schering ^[1]. It is marketed in oral form under names such as Progynova and as long-acting oil-based injections under names such as Delestrogen and Progynon Depot ^[1][3]. Oral tablets provide a once-daily dose, whereas intramuscular injections release the hormone slowly over one to several weeks depending on the amount given ^[1].

The most common use of estradiol valerate is menopausal hormone therapy, where it treats hot flashes, vaginal atrophy, and other symptoms of low estrogen, often combined with a progestogen such as dienogest to protect the lining of the uterus ^[1][2]. It is also used in feminizing hormone therapy and appears in some combined oral contraceptives; comparative reviews note that estradiol and its valerate ester are weaker than, and may stimulate the liver's production of clotting proteins less than, the synthetic estrogen ethinylestradiol traditionally used in the pill ^[3]. Pharmacokinetic studies confirm that oral estradiol valerate is converted to estradiol and estrone in the blood and that different formulations can be made bioequivalent ^[4]. Historically it was also given in high doses to treat prostate cancer ^[1].

Estradiol valerate is a prescription medicine available as a generic in many countries ^[1][4]. Its side effects are those of estrogen therapy in general and include breast tenderness and enlargement, nausea, headache, and fluid retention; higher doses can raise the risk of blood clots and affect blood lipids, insulin sensitivity, and prolactin levels ^[1]. As with other estrogens, use is individualized and, in women with a uterus, generally paired with a progestogen ^[1][2].

Estradiol valerate is prescription only and shares the safety profile of estradiol. Common effects include breast tenderness, nausea, headache, bloating, and breakthrough bleeding. The important risks are blood clots and stroke, which run higher with oral estrogen than with skin delivery, gallbladder problems, and overgrowth or cancer of the womb lining if it is used without a progestogen in someone with a womb. Long term combined therapy adds a small breast cancer risk. It is avoided in estrogen sensitive cancers, unexplained vaginal bleeding, active clots, and serious liver disease, and caution is needed in smokers and those with clotting risk factors.

Estradiol is cleared largely by CYP3A4, so inducers of that enzyme drop estrogen levels. Rifampin, rifabutin, carbamazepine, phenytoin, phenobarbital and St John's wort all reduce exposure enough to cause breakthrough bleeding and, where the product is used for contraception, contraceptive failure. Strong CYP3A4 inhibitors push the other way and raise estrogen levels along with the thrombotic and vascular risks that follow.

The sharpest documented problem is with hepatitis C regimens containing ombitasvir, paritaprevir and ritonavir. Combining those with ethinylestradiol caused marked ALT elevations, and ethinylestradiol containing products are contraindicated with them; estradiol and estradiol valerate carry a lower but still flagged risk.

Estrogens raise thyroxine binding globulin, which lowers the free fraction of thyroid hormone and increases the thyroxine requirement in people treated for hypothyroidism. The same shift in binding proteins distorts cortisol and sex hormone binding globulin measurements, so laboratory results taken during estrogen therapy can mislead.

Checking a whole stack? Run it through interactions + stacks.

Estradiol valerate is an ester prodrug of estradiol, the principal natural estrogen, created by attaching a valeric acid chain to the hormone to make it more fat-soluble and longer-acting. It was introduced by the German pharmaceutical company Schering in the 1950s and has since been marketed under names including Progynova for oral use and Delestrogen for long-acting oil injection into muscle.

The chemistry is elegant in its simplicity: once in the body, esterase enzymes in the blood and tissues cleave off the valerate group, releasing plain estradiol that behaves exactly as the natural hormone does. Over the decades it has been employed in menopausal hormone therapy, in feminizing hormone therapy for transgender women, and, historically, in the palliative treatment of prostate cancer. It later became notable as the estrogen component of one of the first combined oral contraceptives to use estradiol rather than a synthetic estrogen.

Estradiol valerate is valued as a versatile and time-tested way to deliver bioidentical estradiol, appreciated for the fact that its effects are essentially those of the body's own estrogen rather than a synthetic substitute. Its ester design gives clinicians flexibility, allowing either a convenient daily tablet or a long-acting depot injection that releases hormone gradually over days to weeks.

In feminizing hormone therapy it is one of the mainstays for developing and maintaining estrogen-dependent characteristics, and in menopausal care it addresses the symptoms and bone effects of estrogen loss. Its long clinical history means its behavior is well understood, though the usual considerations that apply to all estrogen therapy, including effects on clotting risk, remain important and warrant individualized assessment. Because it is metabolized straight into estradiol, many prefer it precisely for that predictability and its bioidentical nature.